Glucose versus lactate in immature brain slices

Related Q&A: Y Ben-Ari writes that ‘Zilberter and Bregestovski and colleagues’ dealt with ‘ketone body metabolites’. What does ketone body metabolite mean? ”

About this post

1. These quotes were first used by Elly Strammer at F1000.com. After she agreed to remove her post from there, she contacted us suggesting that we use the quotes. We thank Elly for her contribution and for further commenting at the Naturally Selected

2. We received many questions regarding this post, quite a few of them concerned the formatting, which was not helping to clearly understand the issue. Because of that, we updated the post making sure to visually indicate quotes belonging to the arguing sides (according to F1000.comNow, remarks related to comments concerning the works of Y. Zilberter et al. are marked as  and remarks by Y. Ben-Ari are marked as 

 ”We demonstrate that in the neonatal brain, Em [membrane potential] and EGABA [reversal potential of GABA-induced anionic currents] strongly depend on composition of the energy substrate pool. Complementing glucose with ketone bodies, pyruvate or lactate resulted in a significant hyperpolarization of both Em and EGABA, and induced a radical shift in the mode of GABAergic synaptic transmission towards network inhibition.” (1)

“The main conclusions of our work are that the inhibitory effect of L-lactate on GDPs is not mediated by mitochondrial energy metabolism, and that glucose at its standard 10 mM concentration is an adequate energy substrate for neonatal neurons in vitro.” (2)

 ”We show that in the presence of glucose, lactate is effectively utilized as an energy substrate, causing an augmentation of oxidative metabolism. Moreover, in the absence of glucose lactate is fully capable of maintaining synaptic function. Therefore, during network activity in neonatal slices, lactate can be an efficient energy substrate capable of sustaining and enhancing aerobic energy metabolism.” (3)

“Lactate is not an efficient replacement for glucose and, as in vivo glucose is always kept at 4-5mM in the brain even in conditions of severe stress.” (4 a)

“The fact is, in the extracellular fluid (ECF) in the brain, glucose concentration is between 1.9 mM and 0.59 while lactate concentration is between 5.1 mM and 0.78 mM (for review, see [9 in this post]). The question arises: why 10 mM glucose in standard ACSF is adequate but 10 mM lactate is not.” (5)

“Clearly, the suggestions of Zilberter and colleagues rely on wrong assumptions and results that have not been reproduced.” (4 a)

“The effect of weak acids on GABA reversal potential and GDP generation was initially described for 4-5 mM concentrations of BHB [ketone body beta-hydroxybutyrate] (Rheims et al. 2009 ), lactate and pyruvate (Holmgren et al. 2010), and was later confirmed by independent research groups for similar concentrations of pyruvate (Tyzio et al. 2011), lactate and propionate (Ruusuvuori et al. 2010).” (6)

“From a clinical perspective, it is interesting to stress that relying on their observations on the positive actions of lactate on metabolism, Zilberter and colleagues have suggested that administration of lactate may be “a novel therapeutic tool to cure Parkinson, Alzheimer, Leigh syndrome and epilepsies” (4a)

 From Brain Fuels: This quotation is taken out of context. The exact piece from (9) reads: “… a growing body of evidence shows that metabolic stress caused by impaired energy homeostasis is a common feature of neurodegenerative disorders (NDDs) such as Alzheimer disease, Leigh syndrome, epilepsy, dementia, multiple sclerosis, neuropathies or ataxias [88] and [89]. We speculate that endogenous ES such as lactate, BHB and pyruvate or their combinations can be efficient in treatingNDD, and would address the cause rather than symptoms. Indeed, the neuroprotective effects of pyruvate have been repeatedly demonstrated in cases of brain ischemia, hypoglycemia, hemorragia, stroke and kainate-inducedepileptic brain damage[90], [91], [92]and [93]. Further research into mechanisms of the effects of ES on fundamental neuronal properties might allow more rapid progress in preventing and managing NDDs.

The comment made on 29 Jul 2011 (4 b) quoted this paragraph with the references removed thus attributing the text solely to (9).

“Considering the compelling and well-known clinical observation that high lactate level is a classical sign of neuron suffering and severe conditions that require rapid intervention, this suggestion is, to say the least, astonishing.” (4 a)

“The bulk of the evidence suggests that lactate is an important intermediary in numerous metabolic processes, a particularly mobile fuel for aerobic metabolism, and perhaps a mediator of redox state among various compartments both within and between cells. Lactate can no longer be considered the usual suspect for metabolic ‘crimes’, but is instead a central player in cellular, regional and whole body metabolism… we might term the period from the 1930s to approximately the early 1970s the dead-end waste product era.” (7)

” It is curious that Dr Zilberter and colleagues refer to metabolism but have never reported measuring it.” (4 b)

“…Ivanov et al. (2011) simultaneously recorded oxygen tension, NAD(P)H fluorescence transients and local field potentials during electrical stimulation of the hippocampal Schaffer collateral pathway in neonatal brain tissue slices from mice. From the very beginning, the authors took great care to ensure both viability and functionality of their preparations. They convincingly demonstrated that surprisingly high superfusion rates with standard artificial cerebrospinal fluid (ACSF) in the slice chamber are required to ensure adequate oxygenation and complete electrical function in blood-free tissue slices. An important implication of this methodological tour de force is that under many previously reported experiments the requirements for viability may been met while the functionality may have been compromised.” (8)

References

  1. Holmgren, C. D., Mukhtarov, M., Malkov, A. E., Popova, I. Y., Bregestovski, P., and Zilberter, Y. (2010). Energy substrate availability as a determinant of neuronal resting potential, GABA signaling and spontaneous network activity in the neonatal cortex in vitro. J. Neurochem. 112, 900–912.
  2. Ruusuvuori E et al. (2010). Spontaneous network events driven by depolarizing GABA action in neonatal hippocampal slices are not attributable to deficient mitochondrial energy metabolism. J Neurosci. Nov 17; 30(46):15638-42
  3. Ivanov A, Mukhtarov M, Bregestovski P and Zilberter Y (2011) Lactate effectively covers energy demands during neuronal network activity in neonatal hippocampal slices. Front. Neuroenerg. 3:2.
  4. Ben-Ari Y.  a) Faculty of 1000, 06 Jan 2011, evaluation,  b) 29 Jul 2011, comment.
  5. Zilberter Y. Faculty of 1000, 19 May 2011 and July 14 2011, comments.
  6. Khakhalin A (May 18, 2011). Questioning the depolarizing effects of GABA during early brain development. J Neurophysiol doi: 0.1152/jn.00293.2011.
  7. Mendel I. Faculty of 1000, 04 Jun 2011, comment (Currently the comment is removed).
  8. Kasischke K (2011) Lactate fuels the neonatal brain. Front. Neuroenerg. 3:4. doi: 10.3389/fnene.2011.00004
  9. Zilberter Y, Zilberter T, Bregestovski P. (2010) Neuronal activity in vitro and the in vivo reality: the role of energy homeostasis. Trends PharmacolSci 31:394–401.

F1000 and the lactate controversy

Q&A and FAQ (archived) :: Ongoing Q&A :: Neuroscience Q&A and FAQ

Question: Hi Tanya,

I am fascinated by development at the Faculty of 1000 started by Y. Ben-Ari. I couldn’t contain myself and posted a comment there. However, I felt a little out of place being just a student arguing with a real scientist. So I still have a couple of questions to ask you.

1. Y Ben-Ari writes there that “Zilberter and Bregestovski and colleagues” dealt with “ketone body metabolites”. What does ketone body metabolite mean? From the articles (Rheims et al., 2009; Holmgren et al., 2010) Y. Ben-Ari refers, I could only find beta-hydroxybutyrate and basing on my textbook, I thought that ketone bodies are metabolized in the brain resulting in CO2, HCO3- and acetone.”]

2. Y Ben-ari argues with your statement and here’s his exact words: “Zilberter and colleagues have suggested that administration of lactate may be “a novel therapeutic tool to cure Parkinson, Alzheimer, Leigh syndrome and epilepsies”. What did you mean the “tool to cure”?

Thank you!

Ingrid

Answer: Hi Ingrid,

The phrase “ketone body metabolites” is used very scarcely and I’ll give you exact usage of it, then I’ll explain what you probably know already from your textbook.

From those authors who use this phrase, most of them refer to the work of Miles et al. (1), the accurate quote of which is: “ketone body metabolites (CO2, bicarbonate and acetone)” (1). Fontain et al. (2) mention ketone bodies metabolites listing them as beta-hydroxybutyric acid and acetoacetic acid, which is not exactly accurate since they both are ketone bodies themselves.

Other than that, the phrase has a different meaning, like this: “Fatty acids and their ketone body metabolites may serve as afferent signals to modulate food intake” (3). Clearly, ketone bodies are meant as metabolites of fatty acids, again a textbook information.

A citation from very recent reference (4): “Ketone bodies, as described here, comprise acetoacetic acid (AcAc), D-3-hydroxy-n-butyric acid (3HB), and acetone.” Note that they are ketone bodies, not ketone body metabolites.

Now, from the textbook (5): In muscle and brain, ketone bodies yield ATP + CO2 (p. 905); Acetoacetate  + H2O -> Acetone + HCO3- (p. 920)

None of the the two articles Y Ben-Ari refers to in his evaluation concerns anything other than beta-hydroxybutyrate, not other ketone bodies, not ATP, CO2 or HCO3-, or acetone.

As to your question number 2, text concerning “therapeutic” might be from (6): “Our hypothesis predicts that the adequate delivery of energy substrates may interrupt this pathological spiral of events and provide therapeutic options targeting the cause of pathologies rather than their symptoms”. However, there’s nothing wrong with this statement  even as it’s cited (excluding of course the words “cure”, which I can hardly imaging being in the Zilberter and coauthors’ vocabulary) and many authors describe and discuss metabolic crisis in connection with neurodegenerative diseases.

1. Miles J et al., (1980) Determination of 14C radioactivity in ketone bodies: a new, simplified method and its validation. J Lipid Res, 21, 646-650.

2. Fontaine M et al. (1996) Acylcarnitine removal in a patient with acyl-CoA beta-oxidation deficiency disorder: effect of L-carnitine therapy and starvation Clinica Chimica Acta 252; 109-122

3. Bray GA “A Guide to Obesity and the Metabolic Syndrome: Origins and Treatment” CRC Press, 2011.

4. Sass JO (2011). Inborn errors of ketogenesis and ketone body utilization. J Inherit Metab Dis DOI 10.1007/s10545-011-9324-6

5. Lehninger, A. L. (2005). in Principles of Biochemistry, 4th Edn, eds D. L. Nelson and M. M. Cox (W. H. Freeman),

690–740.

6. Holmgren, C. D., Mukhtarov, M., Malkov, A. E., Popova, I. Y., , P., and Zilberter, Y. 2010). Energy substrate availability as a determinant of neuronal resting potential, GABA signaling and spontaneous network activity n the neonatal cortex in vitro. J. Neurochem. 112, 900–912.

Q&A: Puzzled by a poster at SFN

Original Q&A :: About these Q&A :: Other Q&A

Q: Hi Tanya,

It’s Ingrid again, amused by my beloved topic of excitatory GABA, this time, at SFN 2010. I’m not fortunate enough to be there but nice guys
posted some posters’ photos on our itranet.

My two questions are:

1. Why in table 1, they give SERUM levels of BHB, pyruvate and lactate although the discussion is going on around neuronal behavior?!  Looks
just plane and simple illiterate!

2. Conclusion reads: “Therefore, conventional glucose containing ACSF provides adequate energy supply in vitro.” Do they forgot or
intentionally omitted mentioning immature brain?  A renown expert in developmental metabolism, Dr. Nehlig, one of the coauthors, is it
possible that she agrees with this conclusion, namely that in neonatal slices, neurons happily run on glucose – or this conclusion does not
relate to immature neurons? If so, what this poster is about other than attempting to scandalize Dr. Zilberter team and work?

Thank you Tanya for your time and patience with us inpatient students :)

Ingrid

A: Dear Ingrid,

Remembering your previous question on this topic ,  I guess it’s about Dr Ben-Ari poster, right? I  saw this poster’s photo.

Let’s see how to politely answer your questions. It’s a simple “I have no idea” to your question number 1. You might want to read what surrounds neurons in real brain including energy substrate concentrations in our TIPS review (1), but why SERUM [my capitals] fascinates the authors more than ECF is an enigma to me as it is to you (2).

As to the question number 2, your hypothesis is very interesting although does not help me to answer. Indeed, in all articles by Dr. y Zilberter’s team, works of Dr Nehlig are respectfully and consistently referred to. An example from the Tips review: “Once the onset of suckling takes place, KB become the major fuel for rat brain development” (3) and “In the postnatal developing rat brain, glucose utilization is limited to only about 20% of adult levels” (4).

Notwithstanding, as you quote from the SFN poster, “Therefore, conventional glucose containing ACSF provides adequate energy supply in vitro” –  certainly it cannot be about immature brain. But the title clearly reads: “Depolarizing action of GABA in hippocampal and neocortical IMMATURE [my capitals] neurons depends neither on ketone bodies nor on pyruvate/lactate”. I’m lost here. Sorry I failed!

References

1. Trends Pharmacol Sci. 2010 Sep;31(9):394-401
2. Barriers and fluids that connect and divide blood, brain, and neurons
3. A. Nehlig, Brain uptake and metabolism of ketone bodies in animal models, Prostaglandins Leukot. Essent. Fatty Acids 70 (2004), pp. 265–275
4. A. Nehlig et al., Quantitative autoradiographic measurement of local cerebral glucose utilization in freely moving rats during postnatal development, J. Neurosci. 8 (1988), pp. 2321–2333

You must not fool yourself – and you are the easiest person to fool

Ethics in science — 7:38 am

“The first principle is that you must not fool yourself—and you are the easiest person to fool…. After you’ve not fooled yourself, it’s easy not to fool other scientists. You just have to be honest in a conventional way after that.” — Nobel laureate physicist Richard P. Feynman.

Says David Goodstein, Caltech (On Fact and Fraud: Cautionary Tales from the Front Lines of Science (Princeton University Press, 2010):

“A scientist should never be motivated to do science for personal gain, advancement or other rewards.”
“Scientists should always be objective and impartial when gathering data.”
“Scientists must never believe dogmatically in an idea or use rhetorical exaggeration in promoting it.”
“Scientists should never permit their judgments to be affected by authority.”

Do you think the above maxims reflect how science works in practice?

Source:
July 2010 Scientific American Magazine. M. Shermer When Scientists Sin. Fraud, deception and lies in research reveal how science is (mostly) self-correcting


COMMENT by Elly Strammer

June 20 2011

“Do you think the above maxims reflect how science works in practice?”  Well, I’ve read the post http://brainfuels.com/2011/06/glucose-or-lactate-as-fuels-in-immature-brain-whose-primacy/ and my answer is a big NO!


Why physicians have been taught to fear ketosis

Ketosis is natural and good for you

The large categories of disease for which ketones may have therapeutic effects are:
(1) diseases of substrate insufficiency or insulin resistance,
(2) diseases resulting from free radical damage,
(3) disease resulting from hypoxia.

Source: Veech, R L : Chance, B : Kashiwaya, Y : Lardy, H A : Cahill, G F Jr. Ketone bodies, potential therapeutic uses. IUBMB-Life. 2001 Apr; 51(4): 241-7
To leave a comment or question click here